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ABSTRACT
Despite high levels of homology, transcription
coactivators p300 and CREB binding protein (CBP)
are both indispensable during embryogenesis. They
are largely known to regulate the same genes. To
identify genes preferentially regulated by p300 or
CBP, we performed an extensive genome-wide-
survey using the ChIP-seq on cell-cycle
synchronized cells. We found that 57% of the tags
were within genes or proximal promoters, with an
overall preference for binding to transcription start
and end sites. The heterogeneous binding patterns
possibly reflect the divergent roles of CBP and p300
in transcriptional regulation. Most of the 16103
genes were bound by both CBP and p300.
However, after stimulation 89 and 1944 genes were
preferentially bound by CBP or p300, respectively.
Target genes were found to be primarily involved
in the regulation of metabolic and developmental
processes, and transcription, with CBP showing a
stronger preference than p300 for genes active in
negative regulation of transcription. Analysis of
transcription factor binding sites suggest that CBP
and p300 have many partners in common, but AP-1
and Serum Response Factor (SRF) appear to be
more prominent in CBP-specific sequences,
whereas AP-2 and SP1 are enriched in
p300-specific targets. Taken together, our findings
further elucidate the distinct roles of coactivators
p300 and CBP in transcriptional regulation.
INTRODUCTION
The primary mechanism to control cellular processes, such
as proliferation and diﬀerentiation, is by regulation of
gene expression [reviewed in (1–3)]. Gene expression is a
highly coordinated process that results in the synthesis of
messenger RNA after recruitment of the pre-initiation
complex, histone modifying factors and transcription
factors (TFs) to regulatory regions of the chromatin.
The histone modiﬁcations that take place during this
process, including methylation and acetylation, play a
critical role in gene regulation, and defects have been
implicated in many pathological conditions from cancer
to autoimmune diseases (4–6). Recently, chromatin
immunoprecipitation (ChIP) has been extensively applied
in combination with high-throughput sequencing to map
genome-wide chromatin modiﬁcation proﬁles in human
T cells (7,8) and in mouse ES cells (9). Binding sites of
the insulator binding protein CTCF (7), RNA pol II (7,10)
and several TFs (11–14) have also been mapped. The
acetylation proﬁle in primary human T cells was further
investigated by determining the binding of several histone
deacetylases (15) and histone acetyltransferases (HATs)
including p300. Binding of p300 was found both at
genes and at intergenic DNase hypersensitive sites, con-
sistent with binding to enhancers, found in other p300
ChIP-seq experiments (16,17).
The HAT p300 and its family member CREB-binding
protein (CBP) are transcription coactivators for a broad
range of genes involved in multiple cellular processes such
as proliferation, diﬀerentiation, apoptosis and DNA
repair [reviewed in (18,19)]. In addition, a number of
studies suggested the involvement of p300 and CBP in
pathological disorders such as the Rubinstein–Taybi
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cancer [reviewed in (21)]. Originally, CBP was identiﬁed
through its association with the phosphorylated TF
CREB (22), but CBP and p300 also interact with many
other TFs, such as cJun (23), p53 (24) and MyoD (25) via
conserved domains (CH1, CH3, KIX and SID). Apart
from the transcriptional regulation through acetylation
of histones and other factors, p300 and CBP can also
act as a bridge or as a scaﬀold between upstream TFs
and the basal transcription machinery.
A crucial role for both p300 and CBP in development
was shown in mice with a homozygous deletion of ei-
ther gene (Ep300 and Crebbp for the proteins p300 and
CBP) resulting in embryonic lethality at a very early
stage (26,27). Interestingly, the double heterozygous
Ep300
+/–/Crebbp
+/– mice also die in utero (26), indicating
that a ﬁne-tuned balance in the expression of both
proteins is needed to ensure the normal development.
From phenotypic changes in the knock-out mice it is
indicated that p300 and CBP have diﬀerent functions,
which has been further illustrated in additional
in vivo studies (28–30). A comparison between the
acetyltransferase domains of p300 and CBP showed that
they diﬀer structurally (31). In part, this might contribute
to their functional diﬀerences. However, the current
detailed mechanism of action of p300 and CBP and
the diﬀerences between these transcription coactivators
is not clear.
In contrast to the in vivo situation, most studies with
tissue culture cells show similar functions for p300 and
CBP, and only limited diﬀerential roles for p300 and
CBP have been described [reviewed in (18)]. To obtain
a better insight into genes regulated by the general tran-
scription coactivators p300 or CBP next-generation
sequencing of ChIP genomic fragments (ChIP-seq) (14)
was performed. ChIP-seq and ChIP-on-microarray
(ChIP-chip) have high correspondence in results, but
ChIP-seq oﬀers the advantages of requiring less input
material, potential to identify binding sites with low
aﬃnity, not being limited to target regions (i.e. probes
on a microarray), not having hybridization errors and
it is less costly for whole genome analysis (14). In this
study, we used the glioblastoma cell line T98G. This
cell line can easily be synchronized by serum-deprivation
and reintroduced into the cell cycle upon stimulation
with serum and TPA. Previously, RNA pol II ChIP was
performed in growth factor stimulated T98G cells (32),
and this showed that 30min upon growth factor stimula-
tion pol II occupancy at the promoter of immediate early
genes was maximal. We observed that maximal occu-
pancy of p300 and CBP at the promoter of immediate
early genes was also around 30min (Y.F.M.R., unpub-
lished results).
We show p300 and CBP binding to the chromatin in
quiescent and stimulated cells, and alterations in their
binding to a large number of genes after stimulation. In
most cases there is overlap between regions bound by p300
and CBP, but we also identiﬁed distinct regions of
binding, indicating speciﬁc targets for each of these
acetyltransferases. Bound regions were analyzed genome-
wide for their position relative to genes and were found to
have a preference for transcription start sites (TSSs) and
transcript ends. Interestingly, functional classiﬁcation of
target genes suggests that CBP is more involved in the
regulation of transcription inhibition than p300. A list of
TFs that might be involved in the transcription regulation
of the identiﬁed genes together with p300 and/or CBP was
obtained by searching for enriched TF binding sites
(TFBSs) in the bound regions. Results show previously
established binding partners, and suggest diﬀerences for
p300 and CBP in their preferences for TFs.
MATERIALS AND METHODS
Cell culture, ChIP, qPCR and sequencing
Human glioblastoma T98G cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), penicillin
(100mg/ml) and streptomycin (100mg/ml). Prior to stimu-
lation with serum (20%) and tetradecanoyl phorbol
acetate (TPA 100ng/ml; Sigma), cells were serum
starved for 2–3 days (DMEM supplemented with 0.1%
FBS).
For sequencing, chromatin was isolated from
serum-starved cells (T0) and from cells stimulated for
30min with serum and TPA (T30). Chromatin from T30
samples were prepared in duplicate, each being used for
individual ChIPs, sequencing and downstream analysis. In
addition, for more time-point speciﬁc data (analyzed only
by ChIP and quantitative PCR) we isolated chromatin at
0, 2, 5, 15, 30, 60, 90, 120 and 360min following stimula-
tion. Chromatin was prepared and ChIPs were carried out
as previously described, including fragmentation
by soniﬁcation (33) (fragment size  500bp). Immunopre-
cipitations were performed for p300 using the p300-(2)
antibody produced in our lab (23), and for CBP with a
commercially available antibody (A22 from Santa Cruz).
For Reverse Transcriptase-Polymerase Chain Reaction
(RT-PCR) analysis, RNA was isolated using the SV Total
RNA isolation System (Promega Corporation Benelux),
according to the manufacturers’ protocol, and ﬁrst-strand
cDNA synthesis was performed using 1mg of RNA and
ImProm II reverse transcriptase (Promega Corporation
Benelux).
Quantitative PCR for ChIP and for cDNA samples was
carried out on Applied Biosystems 7900HT Fast
Real-Time PCR System with SYBR Green PCR Master
Mix (Applied Biosystems Europe). Primers were designed
using the Primer Express program from Applied
Biosystems (for sequences of primers see Supplementary
Table S1). Eﬃciency of the ChIP is presented as percent-
age of the input. Expression levels of the genes as
determined by quantitative RT-PCR were normalized to
GAPDH, and fold induction was calculated with reference
to the untreated samples (t=0minutes).
For ChIP-seq all samples were prepared with Illumina’s
DNA sampleprep Kit (FC-102-1001) according to the
manufacturer’s protocol. Single ends of each sample
were then sequenced on a single lane of the Illumina
Genome Analyzer (GAI for samples CBP T0 and T30-1
Nucleic Acids Research, 2010,Vol.38, No. 16 5397and p300 T0 and T30-1, GAII for samples CBP T30-2 and
p300 T30-2) for 36 cycles.
Illumina genome analyzer sequencing analysis
Sequencing results were run through the standard
Illumina GAPipeline (v1.0 for GAI runs and v1.3 for
GAII runs) to convert images to reads (unaligned se-
quences produced by the Illumina Genome Analyzer)
and edit for quality (FIRECREST, Bustard and
GERALD). A general overview of the entire ChIP-seq
analysis is provided in Supplementary Figure S1A. The
reads were then trimmed to the ﬁrst 32bp to remove
lower quality base calls at the 30-end of the read. These
were then run through the developing GAPSS_R (www
.lgtc.nl/GAPSS) pipeline. This pipeline took the reads,
removed the ﬁrst base pair (often low quality compared
to other 50 nucleotides), converted to FASTA format,
aligned to the human reference genome (NCBI build 36)
with Rmap v0.41 (34), permitting up to two mismatches,
and exported tags (the term for aligned reads) into region
ﬁles (merging adjacent nucleotides with at least one
aligned read into one region, followed by compressing
those regions within 100bp into one (based on a range
of compression sizes, see below and Supplementary
Figures S1B and S2). The pipeline also created wiggle
ﬁles [viewable in the UCSC genome browser (35)]. These
tracks had positions with only a single read removed, in
order to create more manageable ﬁles.
All unedited wiggle ﬁles were concatenated to one with
custom Perl scripts and converted to a region ﬁle [a range
of compression windows (20, 50, 100, 150 and 200bp)
were used] with GAPSS_R scripts. The compression
windows account for small gaps in the genomic sequences
covered, such as the result of non-unique genomic se-
quences (Rmap does not map to these). An appropriate
compression size is hard to determine, considering a
bigger window results in less regions (Supplementary
Figure S2) and therefore speciﬁcity, but covers larger
genomic repeats. We settled on a window of 100bp to
retain a large number of regions, while at the same time
accounting for small repetitive elements. This consensus
region ﬁle had the number of tags from the individual
region ﬁles mapped to it with a custom Perl script. To
make data more manageable and reduce background or
very low aﬃnity binding we removed regions with <6 tags
(total over all samples). To further reduce the noise only
regions with at least 1 tag/million reads aligned (18.1 tags
across all total samples) were evaluated. Without applying
this threshold performance was poorer, as addressed in the
results.
To annotate regions we downloaded from Ensembl 54
Biomart (36,37) for all genes (with an HGNC ID) the
chromosomal location, strand, gene start, gene end, tran-
script start, transcript end and gene ID. These were loaded
into a custom mysql database that was queried to
annotate regions for overlap with genes (including
ﬂanking 1kb). We also annotated for distance to the
nearest TSSs and transcript ends. Histograms were
plotted in the statistical language R to visualize the
distance to TSSs and transcript ends.
Statistical analysis
The statistical language R was used to evaluate reprodu-
cibility and overlap across samples and to determine genes
with diﬀerential TF binding across diﬀerent conditions.
To be able to compare data across samples, samples
were scaled to the average total number of tags per con-
dition/coactivator. A square root transformation was
applied before calculating the reproducibility and compar-
ability across samples. This was to stabilize the variance,
inherent to the count process, over the entire intensity
range (38), and to spread the data points better over the
intensity range (Supplementary Figure S3). After this, to
give a better estimation of the comparability of the data
from the diﬀerent samples Pearson’s correlations were
calculated in R. This was done on all regions with abun-
dance >1 tag/million tags and a square root transform-
ation applied before calculating the correlations. The
Pearson’s correlations on the linear scale were slightly
lower.
Subsequently, data were summarized at the gene level
by adding all tags within a gene or its 1kb ﬂanking
regions. To determine the genes diﬀerent between condi-
tions/coactivators Fisher’s exact P-values were calculated
in R. For each individual gene, a two-by-two table
was created containing the number of tags for this gene
in condition 1 and condition 2 and the total number of
tags in condition 1 and condition 2. We then applied the
method of Benjamini and Hochberg to correct for
multiple testing.
Functional classiﬁcation
A list of 250 genes, identiﬁed as most signiﬁcantly diﬀerent
between the time points for each coactivator (T30/T0 with
adj. P-value <0.001), was uploaded in DAVID 2008
(39,40) for functional enrichment analysis. To obtain a
general impression of the types of processes in which
CBP and p300 are involved, functional annotation
charts were generated for the Gene Ontology (GO) term
‘GOTERM_BP_ALL’ (41,42) using a human
background.
In addition, signiﬁcantly diﬀerent genes at T30 were
divided into two groups where either CBP or p300
binding was higher. From these groups, the 250 genes
most signiﬁcantly diﬀerent were uploaded in DAVID
2008 for functional enrichment analysis. Individual
GO-terms with a P-value <0.001 are shown for genes
with higher CBP or p300 binding.
CORE_TF analysis for TF partners of p300/CBP
We took the same signiﬁcant gene sets as from the func-
tional analysis and retrieved the most substantially
sequenced region (most number of tags in this particular
region) for these genes. These regions were extended at
both sides to a ﬁnal length of 2kb and sequences retrieved
with Ensembl Perl API. As a background set, we retrieved
3000 random genes’ TSSs from Ensembl Biomart that
were located on chromosomes 1–22, X and Y and
retrieved the sequences ±1kb from these TSSs. The
regions based on signiﬁcantly diﬀerent genes were
5398 Nucleic Acids Research, 2010,Vol.38, No. 16entered into CORE_TF (43) as experimental sequences
and the random TSS sequences were entered as back-
ground regions. We evaluated enrichment of TFBSs
[deﬁned as TRANSFAC (44) position weight matrices]
in the experimental sequences using the most stringent
match setting (44,45) to minimize false positives.
P-values representing the signiﬁcance of over-
representation were calculated with a binomial test.
RESULTS
Initial sequencing analysis
Stringent regulation of gene expression is fundamental to
control cellular processes such as proliferation and diﬀer-
entiation. The general coactivators p300 and CBP play an
important role in the regulation of gene transcription by
virtue of their acetyltransferase activity. We set out to
determine and compare genes regulated by p300 and
CBP. Chromatin was isolated from serum-starved (T0)
and from stimulated (T30, done in duplo) human glio-
blastoma cells and ChIP-seq performed using CBP-and
p300-speciﬁc antibodies.
Sequence ﬁles generated by the Illumina GAPipeline
were submitted to the NCBI Sequence Read
Archive (SRA; http://www.ncbi.nlm.nih.gov/Traces
/sra: SRS009476, SRS009457, SRS009477, SRS009478,
SRS009479 and SRS009480) (46). The reads passing
quality control were mapped to the human reference
genome and adjacent tags were joined into regions
(Table 1). We also have made sequencing data available
as UCSC hg18 viewable wiggle tracks (excluding pos-
itions with only one tag aligned, Supplementary
materials 1–6).
Preferential binding in genes and promoters
Without applying a threshold of 1 tag/million tags, we
found low overlap of identiﬁed regions in the replicated
samples indicating that regions with low abundance rep-
resent noise (data not shown). With the threshold of 1 tag/
million tags, we found a high consistency in the identiﬁed
regions between all samples (47.96 and 47.43% overlap
between CBP and p300 at T0 and T30, respectively;
Table 2). Concordantly, the reproducibility between bio-
logical replicates was high (Pearson’s correlation: 0.77 and
0.87 for CBP and p300, respectively). A similarly high
correlation was found across the diﬀerent samples
(Pearson’s correlation 0.81 on average between all time
points and coactivators; Supplementary Table S2),
indicating relatively minor diﬀerences in the distribution
of p300 and CBP binding sites across the genome. In sub-
sequent analyses, datasets of the T30 biological replicates
were summed and treated as one sample, which provided
us with high-quality results.
To study the biological implications of our data, we
annotated the regions obtained from sequencing with
Ensembl and found that the sequenced regions covered
16103 annotated genes in total. When looking at condi-
tions and coactivators independently there were 16045,
16075, 15684, and 15996 genes identiﬁed as bound by
CBP at T0 and T30, and by p300 at T0 and T30, respect-
ively. We observed similar percentages of tag in genes and
their 1kb ﬂanking regions in all samples (57.08, 57.10,
57.30 and 59.93% for CBP-T0, CBP-T30, p300-T0 and
p300-T30, respectively). Therefore, both CBP and p300
appear to be needed to maintain basal levels of expression
in quiescent cells as well as to activate or repress transcrip-
tion after serum stimulation.
Table 1. Sequencing results
CBP p300
t (min) No. of
reads
No.
aligned
Percentage
of aligned
No. of
regions
a
No. of
reads
No.
aligned
Percentage
of aligned
No. of
regions
a
T0 5498759 4018590 73 713141 6327413 5086340 80 841029
T30
1 6389605 4849826 76 889781 6446269 5156450 80 802627
T30
2 6047530 5001204 83 851988 6065594 5124836 84 684222
The total number of reads, reads aligned, percentage aligned and number of regions created (
aafter compressing regions within 100bp into one and
excluding regions composed of only a single tag) for each condition (T0: quiescent cells and T30: 30min after growth factor stimulation) and for each
transcription coactivator (CBP or p300). For T30-independent biological replicates were sequenced as indicated by
1 and
2.
Table 2. Region overlap
CBP T0 CBP T30
2 CBP T30
1 p300 T0 p300 T30
2 p300 T30
1
CBP T0 267562 129089 133493 140245 120092 134799
CBP T30
2 315020 143160 152520 136405 148669
CBP T30
1 322556 151519 136685 150180
p300 T0 322354 138933 158708
p300 T30
2 267804 139592
p300 T30
1 304880
The number of regions, after applying thresholds (>1 tag/million tags), overlapping between conditions (T0 and T30) and coactivators (CBP and
p300). For T30-independent biological replicates were sequenced as indicated by
1 and
2.
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enhancers (15,16). First, we evaluated the distance for all
regions bound by CBP or p300 to the nearest TSS and
transcript end (polyadenylation site). We found that
genome-wide, 57% of all tags could be annotated to
genes (±1kb) and a clear preference for TSSs and tran-
script ends was observed (Figure 1A and B). There were
no apparent diﬀerences between the proﬁles of CBP and
p300 (data not shown). Also, diﬀerent from what has been
shown before for most TFs or histone modiﬁcation maps,
p300 and CBP show three distinct patterns of binding,
including a distinguished peak (binding to a speciﬁc site
like the TSS, e.g. ZNF688; Figure 1C), binding across the
gene with no clear preference for a speciﬁc region (e.g.
EGR1; Figure 1D), and so-called ‘U-shaped binding’
(binding across the gene with a bias toward the TSS and
transcript end, e.g. DUSP1; Figure 1E).
Diﬀerential binding by CBP and p300
With most data corresponding to a genic region, we
focused our following analyses to genes, and on those
regions within 1kb upstream of TSS and 1kb downstream
of the transcript end, (16103 genes across all four
samples). Since we were especially interested in genes
that were preferentially regulated by p300 or CBP
during entry in the cell cycle, a Fisher’s exact test was
performed to determine statistically signiﬁcant diﬀerences
in the total number of tags localized to a certain gene in
diﬀerent conditions (between time points or between
coactivators) studied.
Despite high overlap in regions bound by CBP and p300
in quiescent and in stimulated cells (Table 2), there was
also a considerable number of quantitative changes in
CBP and p300 binding upon stimulation. Signiﬁcant dif-
ferences between p300 and CBP binding was found for 120
and for 1611 genes at a false discovery rate of 0.1% at T0
and T30, respectively (Figure 2A). At a false discovery
rate of 1% this was 256 and 2502 at T0 and T30, respect-
ively (Supplementary Table S3). From the genes diﬀeren-
tially bound by p300 and CBP in quiescent cells (T0), only
25 did not have signiﬁcantly diﬀerent binding upon
growth factor stimulation (Figure 2A). These results
indicate very high overlap in genes bound by p300 as
well as by CBP in the quiescent state and a divergence
of the roles of CBP and p300 mainly during periods of
activated transcription. Analysis of the 250 genes that
were most signiﬁcantly diﬀerent in our data, showed
that for the majority p300 binding was higher than CBP
binding (191 and 227 of 250 genes, for T0 and T30,
respectively).
When comparing between time points, we found 765
genes diﬀerentially bound by CBP and 2620 genes
Figure 1. Histogram for the compilation of ChIP-seq regions showing the frequency of the distance from the localization of a sequenced region to
the nearest transcription start site (blue) and transcript end (red) [full plot in (A), zoomed in (B)], which indicates a preference for binding to TSSs
and transcript ends. Representative examples of the diﬀerent types of binding are shown as custom tracks on the UCSC genome browser: binding to
a speciﬁc site resulting in a ‘peak’ (C), binding across the gene (D), and ‘U-shaped binding’, with binding across the gene with preference for both
TSS and transcript end (E). The y-axis indicates the number of tags aligned at each position in the genome. The black line in Figure 1C–E indicates a
value of 5 tags in the custom tracks.
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which were most signiﬁcantly diﬀerent between time
points, the majority (209 and 155 for CBP and p300, re-
spectively) demonstrated higher binding for both, p300
and CBP, at T30 when compared to T0. In addition, the
majority of genes with changed binding of CBP after
stimulation also demonstrated diﬀerence in binding by
p300 (676 out of 765 and 2620 genes, respectively;
Figure 2B). The apparently higher number of genes with
signiﬁcant changes in p300 binding is likely due to the
higher eﬃciency of the p300 antibody causing better
signal-to-noise ratios and higher sensitivity in the detec-
tion of quantitative changes in binding proﬁles (see
below). The high level of overlap between coactivators
can explain the restricted number of diﬀerences found
thus far in functions of p300 and CBP.
We present a full list of genes bound by CBP and p300
at T0 and T30 in Supplementary material 7. Table 3 lists
the 10 genes for which levels of binding diﬀer most signiﬁ-
cantly between the four samples. Among the genes with
strongest CBP and p300 binding and most signiﬁcantly
diﬀerent between T30 and T0 are many immediate-early
genes that are bound by both p300 and CBP (Table 3; e.g.
ATF3, FOSB and DUSP1).
Validation
To validate our results and to reﬁne the temporal reso-
lution of the experiment, genes were selected to further
characterize with ChIP and quantitative PCR in a
time-course from 0 to 360min following stimulation
with serum and TPA. The genes included genes bound
by both CBP and p300 and genes unique to one of the
coactivators, and spanned a wide range of signiﬁcance
values (Figure 3E). In general, the recovery obtained (as
a percentage of the input) for CBP is lower than for p300
(Figure 3A–D), consistent with the generally lower
number of tags for CBP in each region of the ChIP-seq
experiment (signiﬁcant quantitative correlation between
results of the qPCR and ChIP-seq experiment for the
genes presented here are shown in Supplementary
Figure S4). The qPCR results also conﬁrm the diﬀerential
binding across time points established with ChIP-seq
analysis for all genes analyzed (Figure 3A–D and
Supplementary Figure S5), and demonstrate that for
most genes the temporal binding pattern is comparable
between CBP (black bars) and p300 (white bars). This is
true for the increased binding to the promoter of CTGF,
as well as for the decreased binding to the promoter of
ZNF608 in stimulated cells compared to unstimulated cells
(Figure 3A and B). Binding to the promoter of CDK5
diﬀers for p300 and CBP (Figure 3C). Binding of p300
is increased in time with a maximum at 60min
post-stimulation, while there is hardly any change in the
binding of CBP. These results correlate with the statistical
analysis, that demonstrated signiﬁcant changes between
P300 and CBP at T30, and a signiﬁcant increase in P300
but not CBP binding between T30 and T0 (Figure 3E).
The binding of P300 and CBP to the SERPINE gene
increased signiﬁcantly over time (P-value of 1:88   10 17
for CBP T30 versus T0 and 1:59   10 24 for p300 T30
versus T0). Inspection of the wiggle track (Figure 3D)
revealed that p300 and CBP bound mainly to the
30-UTR and to a lesser extent to the region around the
TSS of the SERPINE1 gene. Also, the small increase
observed around the TSS could be conﬁrmed by qPCR.
The wiggle ﬁle for SERPINE1 also shows a stronger
binding >2kb upstream of the TSS (Figure 3D). The
interaction to this putative enhancer region and the
change upon stimulation was also conﬁrmed by qPCR
of ChIP samples (Supplementary Figure S5J).
To evaluate whether changes in p300 and CBP binding
also aﬀected gene expression, we performed quantitative
RT-PCR for the genes CTGF, ZNF608, CDK5 and
SERPINE1 (Figure 3A–D: the line in the graphs shows
fold induction in the time course). For the three genes with
increased binding, two (CTGF and SERPINE1) show
Figure 2. Genes diﬀerentially bound by CBP and p300 (A) and between time points (B). P-values (Fisher’s exact test) for the indicated comparisons
were sorted in rising order and plotted (Upper panels). Under the null hypothesis of no signiﬁcant diﬀerences, this would give a straight line on the
diagonal. However, as becomes evident by the curve shape there is a bias towards low P-values. The number of genes with signiﬁcant diﬀerences
between conditions are indicated in the graphs (false discovery rate of 0.1%). Venndiagrams (Lower panels) demonstrate the number of signiﬁcantly
diﬀerent bound genes, as shown in the plots above, that overlap between time points (A) or coactivators (B).
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in expression over time, consistent with decreased binding
of p300/CBP. CDK5 did not show any diﬀerences in ex-
pression. This is consistent with the uniform levels of CBP
binding over time, but not with the increased binding of
p300. Most likely, for CDK5 and possibly also for other
genes binding of p300/CBP is not suﬃcient to induce the
expression but other factors that play a critical role are
also required. Obviously, gene expression is a complex
process and highly variable between genes, so only
detailed studies can unravel the role of speciﬁc factors.
Biological processes coordinated by p300 and CBP
To get an impression of the biological implications of p300
and CBP binding, we clustered genes regulated by CBP
and p300 into functional pathways. We used DAVID 2008
(39,40) to classify the 250 genes most signiﬁcantly diﬀering
between time points (for both CBP and p300). The
analysis (P-value<0.001) shows that CBP as well as
p300 are mainly involved in transcription regulation of
genes controlling developmental processes, metabolic
processes (such as NR4A, CRISPLD2, CRIM1,
CYCLIN-L1 and PER1) and of genes coding for
proteins that control gene expression (such as ATF3,
FOSB, SP3 and HES1; see Supplementary material 8).
Next, using DAVID 2008 we wanted to specify in more
detail whether certain groups of genes were preferentially
bound by CBP or by p300. Remarkably, in the cluster of
genes regulating transcription, those with signiﬁcantly
higher CBP than p300 binding are involved in negative
regulation of transcription (Table 4, and Supplementary
Table S4C and D). Another interesting observation for
genes preferentially bound by CBP is the presence of
clusters related to signal transcription/cell communi-
cation. In the list obtained for higher levels of p300,
mainly clusters relate to transcription and metabolic
processes are found.
Analysis of ChIP-seq regions for consensus TFBSs
p300 and CBP do not bind DNA directly, but regulate by
binding to many diﬀerent protein partners. Therefore, to
identify (DNA-binding) partners of p300/CBP, we looked
for enrichment of TFBSs in and around the regions bound
by CBP and/or p300 in the 250 genes that diﬀer most
signiﬁcantly between time points (the same genes that
were used for DAVID analysis). We found a signiﬁcant
over-representation of AP-1, CREB, NFKB and SRF
binding sites in the gene regions bound by both CBP
and p300 (Table 5 and Supplementary material 9), which
are known to be regulated by CBP and/or p300 (47). As
mentioned before, there is more binding of p300 and CBP
to the chromatin at T30 after stimulation. Therefore, en-
richment of the TFBSs in our sequences likely reﬂects
increased binding of these factors upon growth factor
stimulation.
We also compared genes signiﬁcantly diﬀerent between
coactivators at T30 using the same lists of 250 genes as
used for the functional classiﬁcation. CREB and YY1 are
signiﬁcantly enriched in both gene sets (Table 5; all results
are presented in Supplementary material 9). However,
CBP binding was found to correlate more with AP-1
and SRF binding partners than p300, whereas p300
Table 3. Gene Top 10
CBP T30 Versus T0 p300 T30 Versus T0
Gene P-value Ratio Gene P-value Ratio
CATSPER3 0 2.58 THBS1 6:13   10 251 6.07
ATF3 5:58   10 101 4.51 ATF3 1:50   10 240 5.83
TRIP13 4:63   10 94 11.07 FOSB 2:22   10 213 14.03
CYR61 4:15   10 80 6.43 CYR61 1:27   10 187 6.33
FOSB 5:04   10 75 10.03 EGR1 1:66   10 178 14.11
SMAD3 8:18   10 72 2.09 TPM1 2:25   10 175 4.81
TMEM49 4:60   10 71 2.32 DUSP1 2:05   10 147 6.81
MYH9 2:15   10 69 2.39 MYH9 8:27   10 144 2.84
CRISPLD2 1:45   10 67 2.89 NR4A1 4:74   10 143 13.16
THBS1 1:32   10 66 4.15 CRISPLD2 1:45   10 140 4.04
T0 p300 Versus CBP T30 p300 Versus CBP
Gene P-value Ratio Gene P-value Ratio
CXXC1 8:28   10 229 22.71 CXXC1 3:06   10 43 20.32
AKT1S1 1:39   10 192 6.03 MKKS 1:66   10 41 3.87
FBXL19 9:96   10 172 5.56 CATSPER3 1:07   10 30 1.44
MKKS 1:67   10 154 4.73 AKT1S1 6:27   10 24 4.46
C3orf19 2:39   10 135 7.93 FAM40A 1:94   10 22 4.21
BSCL2 3:52   10 130 8.25 FBXL19 1:09   10 21 3.27
THBS1 5:46   10 120 2.1 ZNF350 1:09   10 21 9.14
MADCAM1 1:24   10 112 7.85 METTL3 1:50   10 19 13.47
ZNF175 1:01   10 103 17.86 MADCAM1 1:30   10 18 7.2
C1orf174 1:17   10 102 9.84 C1orf174 1:84   10 17 7.25
Top 10 genes that are most signiﬁcantly diﬀerent between time points and coactivators according to the P-values of the Fisher’s exact test. The ratio
shows the quantitative diﬀerence in binding as expressed by the number of tags between the two samples that are compared: from T30 and T0 (upper
half of the table) and from p300 and CBP (lower half of the table).
5402 Nucleic Acids Research, 2010,Vol.38, No. 16Figure 3. ChIP-analysis for time-course experiment (0, 2, 5, 15, 30, 60, 90, 120 and 360min after stimulation of serum-starved T98G cells with serum
and TPA). Shown are graphs for qPCR results [x-axis: time in minutes; left y-axis: ChIP recovery in percentages of the input; right y-axis: fold
induction for the RT-qPCR with reference to the untreated samples (t=0min)] and screen-shots from custom tracks of the UCSC genome browser
for the ChIP-seq data (T0 and T30 only) for CTGF (A), ZNF608 (B), CDK5 (C) and SERPINE1 (D). White bars: p300 ChIP; black bars: CBP ChIP;
RT-qPCR data are indicated as dots, interconnected; arrows in the screen-shots indicate the position of the PCR-amplicon. Also indicated for these
genes is the adj. P-value and the ratio diﬀerence between time-points (T30 versus T0) and coactivators (p300 versus CBP) of the total number of
reads along the whole gene, plus 1kb up- or downstream from all ChIP-seq data (E).
Nucleic Acids Research, 2010,Vol.38, No. 16 5403binding was more correlated to AP-2, E2F and
SP1-binding. These results indicate that CBP and p300
share some, but not all, regulatory partners.
DISCUSSION
Transcription coactivators CBP and p300 share high levels
of homology and, in many cases, the same regulatory
regions are targeted for transcription regulation. This is
in contrast with the fact that both proteins are indispens-
able during embryogenesis. To investigate which genes are
regulated, and whether there is a diﬀerence in those
regulated by p300 and by CBP upon growth factor stimu-
lation a genome-wide screen was performed in T98G cells.
Although there is a high concordance between binding
targets of p300 and CBP, and both seem to regulate the
same biological pathways, we have identiﬁed signiﬁcant
diﬀerences in the levels and targets of binding. These dif-
ferences include the diversity in the regulation of genes
involved in transcription, and in cell death and cell
adhesion. In addition, regulatory regions of these genes
showed signiﬁcant diﬀerences in binding sites of other
TFs and TF families such as AP-1, AP-2, SP1, E2F and
SRF.
It is well established that p300/CBP associate to both
enhancers and TSSs. Previous studies have focused on the
enhancer-binding of p300 (15–17). Although we also
found examples of enhancer-binding, over 57% of all
tags are within genes or proximal promoters (±1kb),
and genome-wide we ﬁnd that binding is primarily
located around TSSs and to some extend also to transcript
ends (Figure 1A and B). Therefore, we chose to focus our
analysis of CBP/p300 in relation to genic regions. In all,
we found 16103 genes bound by CBP or p300 at T0 or
T30, with over 97.4% of genes bound by both coactivators
at both time points.
When analyzing the binding of CBP/p300 to genes, we
did not only observe distinct regions of binding. There was
a high variety in binding patterns for both coactivators.
This includes binding to a clear and distinct region (e.g. to
the TSS; referred to as ‘peak’), binding across the gene, or
a combination of more prominent binding around the TSS
and the transcript end, as well as binding across the
gene (in the text referred to as ‘U-shaped binding’;
Figure 1C–E).
At present, the mechanisms that determine the di-
verse binding patterns remain to be established.
Possibly, it is dependent on the way p300/CBP regulate
transcription of a particular gene. Both, p300 and CBP
can bind to speciﬁc TFs, and this might result in a
distinguished peak around the TSS and transcript end.
In addition, p300 and CBP regulate chromatin structure
via the acetylation of histones, thereby making the
chromatin more prone to be targeted for transcription.
This might account for binding (to the histones) across
the gene. Binding across a gene was previously described
to occur also by protein kinases (48). Chow et al. (48)
propose that in this way the kinases may contribute to
transcription initiation and elongation, or processes
such as 50 capping, and splicing. Binding to both the
TSS and transcript end has previously been observed
for RNA polymerase II (49). Interaction between CBP/
p300 and RNA polymerase II (50) may explain the
presence of similar ChIP-seq patterns for these
acetyltransferases. Enrichment at the TSS might correlate
to the longer time needed for the transcription initiation
compared to transcript elongation. The peak at the tran-
script end might correlate to widespread transcription of
Figure 3. Continued.
5404 Nucleic Acids Research, 2010,Vol.38, No. 16antisense transcripts (51), a phenomena that is particularly
prominent in the 30-end of genes (52).
Our ChIP-seq data are from arrested cells and from cells
30min after stimulation. Therefore, over-representation of
genes required early in the cell cycle was expected at T30.
The number of reads correlates roughly to the binding
aﬃnity of proteins for that region and immediate-early
genes are among the genes with the highest number of
tags. Analysis of a number of these genes with quantitative
RT-PCR (Figure 3A, Supplementary Figure S5 and data
not shown), also showed increase in gene expression for
immediate-early genes. Our data suggest that at T30 CBP
and p300 are more intimately involved in the regulation of
transcriptional activation of immediate-early genes
compared to other groups of genes. Consistently, Tullai
et al. (32) previously published microarray data on gene
Table 4. Functional classiﬁcation for genes bound by CBP or p300
T30 p300 higher than CBP
ID (GO:#) Term Count % P-value Enrichment
0010467 Gene expression 81 38.76 2:57   10 12 2.06
0044237 Cellular metabolic process 127 60.77 3:75   10 10 1.44
0008152 Metabolic process 135 64.59 5:27   10 10 1.38
0044238 Primary metabolic process 126 60.29 1:36   10 9 1.42
0043170 Macromolecule metabolic process 111 53.11 8:79   10 8 1.44
0006350 Transcription 56 26.79 4:10   10 7 1.95
0006139 Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 72 34.45 1:41   10 6 1.66
0045449 regulation of transcription 53 25.36 1:82   10 6 1.91
0016070 RNA metabolic process 58 27.75 3:07   10 6 1.8
0019219 Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 53 25.36 3:64   10 6 1.87
0010468 Regulation of gene expression 54 25.84 4:93   10 6 1.83
0031323 Regulation of cellular metabolic process 54 25.84 1:62   10 5 1.76
0043283 Biopolymer metabolic process 84 40.19 1:78   10 5 1.47
0019222 Regulation of metabolic process 55 26.32 2:08   10 5 1.73
0006351 Transcription, DNA-dependent 48 22.97 3:29   10 5 1.81
0032774 RNA biosynthetic process 48 22.97 3:39   10 5 1.81
0006355 regulation of transcription, DNA-dependent 46 22.01 8:66   10 5 1.77
0006979 Response to oxidative stress 7 3.35 5:49   10 4 6.83
0050794 Regulation of cellular process 67 32.06 8:46   10 4 1.42
T30 CBP higher than p300
ID (GO:#) Term Count % P-value Enrichment
0051056 Regulation of small GTPase mediated signal transductio 18 7.06 8:70   10 9 5.97
0046578 Regulation of Ras protein signal transduction 13 5.10 5:62   10 6 5.36
0007242 Intracellular signaling cascade 38 14.90 2:47   10 5 2.06
0009966 Regulation of signal transduction 21 8.24 2:49   10 5 2.98
0007154 Cell communication 77 30.20 3:31   10 5 1.52
0007165 Signal transduction 71 27.84 6:04   10 5 1.54
0007265 Ras protein signal transduction 13 5.10 9:42   10 5 4.03
0007264 Sall GTPase mediated signal transduction 18 7.06 1:32   10 4 2.94
0007399 Nervous system development 23 9.02 2:26   10 4 2.4
0016481 Negative regulation of transcription 13 5.10 3:31   10 4 3.52
0045934 Negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 13 5.10 7:31   10 4 3.22
Signiﬁcantly enriched GO categories for genes that show higher binding of CBP or p300 at 30min after stimulation with TPA and serum
(ID: GO-category-number, term: description of the GO category; count: number of signiﬁcant genes in this GO category; %: percentage of
signiﬁacnt genes in this GO category; P-value: statistical signiﬁcance of the GO category (P-value from hypergeometric test for over-representation);
enrichment: fold enrichment of signiﬁcant genes compared to the background.
Table 5. Enrichment for TFBSs in CBP/p300 bound sequences
TFBS T30 Versus T0 TFBS T30
CBP p300 CBP>p300 p300>CBP
AP-1 0 0 AP-1 0 2:83   10 2
CREB 8:21   10 5 1:84   10 5 AP-2 9:69   10 1 7:30   10 9
NFKB 4:55   10 7 1:49   10 4 CREB 2:96   10 4 7:60   10 9
SRF 3:41   10 7 1:51   10 5 E2F 2:39   10 1 0
SP1 9:98   10 1 2:21   10 7
SRF 8:81   10 4 2:12   10 1
YY1 2:55   10 6 0
TFBSs with the most signiﬁcant P-values for enrichment in regions bound by CBP and p300 at 0 and 30min after stimulation with serum and TPA.
Nucleic Acids Research, 2010,Vol.38, No. 16 5405expression of serum-starved T98G cells upon growth
stimulation. We found that from 49 immediate-early
genes that were identiﬁed, 36 demonstrated signiﬁcantly
increased binding by CBP and p300 at T30 compared to
T0 in our analysis (3 out of 49 could not be identiﬁed in
Ensembl).
With the time-course experiment, most genes that were
analyzed show maximal binding between 30 and 60min
after stimulation. The time-course experiment conﬁrms
high accuracy of our data since all genes tested,
although diﬀerent levels of signiﬁcance (from 2   10 147
to 9   10 1) and variable ratios of diﬀerence (from 1 to 9)
were chosen, conﬁrm binding of the coactivators and
changes in time.
Binding of p300 and CBP to the chromatin occurs
through the interaction with TFs. To obtain more
insight in transcription regulatory complexes bound by
p300 and/or CBP, we set out to identify possible
partners of CBP and p300 for the genes identiﬁed in our
experiment. Therefore, we analyzed for the enrichment of
TFBSs. When looking at genes with signiﬁcant binding at
T30 for each coactivator, we found some examples of
TFBSs that were found to be speciﬁc only for CBP or
for p300. For example, AP-1 and SRF binding sites
were signiﬁcantly enriched in CBP bound regions, while
AP-2, E2F and SP1 binding sites were more abundant in
p300 bound regions. This may represent TFs that are
regulated during the cell cycle, in most cases, solely by
CBP or p300 and contribute to their unique functions.
We observed overlap in enrichment of TFBSs for
proteins such as YY1 and CREB. Interestingly, YY1 is
known to contribute to cell-cycle regulation and can serve
both, as a transcriptional repressor and an activator (53).
Also, YY1 is known to interact with p300/CBP, as well
as with other TFs identiﬁed in this study (AP-1, AP-2,
NFKB, E2, SP1 and CREB) (53,54,55). Our functional
classiﬁcation suggested that CBP is more associated with
transcriptional repression, whereas p300 is more
associated with transcriptional activation. It could be
speculated that YY1 is a putative partner involved in
this functional diﬀerence between p300 and CBP, while
the p300-YY1 complex might activate transcription
in vivo, the CBP-YY1 complex might account for tran-
scriptional repression.
In the future, it would be valuable to perform ChIP-seq
in the same cell line and conditions with antibodies for the
coactivator speciﬁc TFs in this study (AP-1, AP-2, SP1,
E2F and SRF, and YY1). This will conﬁrm whether
genome-wide CBP/p300 and their speciﬁc regulatory
partners cooperate, and it will help to further elucidate
their role in cell-cycle control. In addition, ChIP-seq
with antibodies speciﬁc to open chromatin states will be
helpful to unravel the mechanisms leading to the diverse
binding patterns.
CONCLUSION
Transcription coactivators CBP and p300 share high levels
of homology and, in many cases, the same regulatory
regions are targeted for transcription regulation. This is
in contrast with the fact that both proteins are indispens-
able during embryogenesis. To investigate which genes are
regulated, and whether there is a diﬀerence in those
regulated by p300 and by CBP upon growth factor stimu-
lation a genome-wide screen was performed in T98G cells.
Although there is a high concordance between binding
targets of p300 and CBP and both seem to regulate the
same biological pathways, we have identiﬁed signiﬁcant
diﬀerences in the levels and targets of binding. In
addition, regulatory regions of these genes also showed
signiﬁcant diﬀerences in binding sites of other TFs such
as AP-1, AP-2, SP1, E2F and SRF.
Besides the diﬀerences in targets of p300 and CBP, we
identiﬁed various binding-patterns that potentially correl-
ate with diﬀerent types of transcription regulation by p300
and CBP. Most interestingly, we observed a so-called
‘U-shaped binding’ with high levels of p300/CBP
at both, TSS and transcript end. Possibly, the
acetyltransferases contribute to other processes such as
transcription elongation and reverse transcription. Taken
together, our data contribute to the improvement of our
knowledge of processes that regulate gene expression by
the transcription coactivators p300 and CBP, and conﬁrm
that regulation by these coactivators is not identical.
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